Proprietary AI analyst is now available
- Public Comps
- Vidavo
Vidavo Valuation Multiples
Discover revenue and EBITDA valuation multiples for Vidavo and similar public comparables like Allurion, NRGene, Impedimed, Renalytix and more.
Vidavo Overview
About Vidavo
Vidavo SA develops mobile applications that help citizens on-the-move and medical professionals manage health and wellness. The company serves health and social care providers, policymakers, insurance companies, ICT firms seeking differentiation, patients, telecom operators, and other health-related stakeholders. Its solutions include vida24, vidatrack, and vidahome.
Founded
2005
HQ

Employees
16
Website
Sectors
Financials (FY)
EV
$10M
Valuation Multiples
Start free trialVidavo Financials
Vidavo reported last fiscal year revenue of $2M and EBITDA of $947K.
In the same fiscal year, Vidavo generated $1M in gross profit, $947K in EBITDA, and $684K in net income.
Vidavo P&L
In the most recent fiscal year, Vidavo reported revenue of $2M and EBITDA of $947K.
Vidavo is profitable as of last fiscal year, with gross margin of 55%, EBITDA margin of 38%, and net margin of 27%.
Financial data powered by Morningstar, Inc.
Vidavo Stock Performance
Vidavo has current market cap of $10M, and enterprise value of $10M.
Market Cap Evolution
Vidavo's stock price is $9.81.
Vidavo share price increased by 0.1% in the last 30 days, and by 107.6% in the last year.
Vidavo has an EPS (earnings per share) of $0.65.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10M | $10M | 0.0% | 0.1% | 13.0% | 107.6% | $0.65 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVidavo Valuation Multiples
Vidavo trades at 3.8x EV/Revenue multiple, and 10.1x EV/EBITDA.
Vidavo Financial Valuation Multiples
As of June 12, 2026, Vidavo has market cap of $10M and EV of $10M.
Vidavo has a P/E ratio of 15.0x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Vidavo Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Vidavo Margins & Growth Rates
In the most recent fiscal year, Vidavo reported gross margin of 55%, EBITDA margin of 38%, and net margin of 27%.
Vidavo Margins
Vidavo Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Vidavo Operational KPIs
Vidavo's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.0M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Vidavo Competitors
Vidavo competitors include Allurion, NRGene, Impedimed, Renalytix, Media Lab, Bullfrog AI, Emimen, Pheton Holdings, VSee Health and Synthetic MR.
Most Vidavo public comparables operate across EHR & Practice Management, Health Data & Analytics, Healthcare Software, B2B SaaS, HealthTech and Vertical SaaS.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | - | - | - | |||
| 1.6x | - | (5.1x) | - | |||
| 1.3x | 1.1x | (1.0x) | (1.1x) | |||
| 3.5x | 3.5x | (0.5x) | - | |||
| 3.9x | - | 12.5x | - | |||
| 62.2x | - | (1.1x) | - | |||
| 0.8x | 0.8x | 12.1x | - | |||
| - | - | - | - | |||
This data is available for Pro users. Sign up to see all Vidavo competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Vidavo
| When was Vidavo founded? | Vidavo was founded in 2005. |
| Where is Vidavo headquartered? | Vidavo is headquartered in Greece. |
| How many employees does Vidavo have? | As of today, Vidavo has over 16 employees. |
| Is Vidavo publicly listed? | Yes, Vidavo is a public company listed on Athens Stock Exchange. |
| What is the stock symbol of Vidavo? | Vidavo trades under VIDAVO ticker. |
| When did Vidavo go public? | Vidavo went public in 2010. |
| Who are competitors of Vidavo? | Vidavo main competitors include Allurion, NRGene, Impedimed, Renalytix, Media Lab, Bullfrog AI, Emimen, Pheton Holdings, VSee Health, Synthetic MR. |
| What is the current market cap of Vidavo? | Vidavo's current market cap is $10M. |
| What is the current revenue of Vidavo? | Vidavo's last fiscal year revenue is $2M. |
| What is the current EV/Revenue multiple of Vidavo? | Current revenue multiple of Vidavo is 3.8x. |
| Is Vidavo profitable? | No, Vidavo is not profitable. |
| How many companies Vidavo has acquired to date? | Vidavo hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Vidavo has invested to date? | Vidavo hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Vidavo
Lists including Vidavo
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.